Allakos (ALLK) Competitors $0.94 -0.07 (-6.94%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ALLK vs. GOSS, QTTB, CYRX, ACIU, CMPS, DSGN, LYEL, SAGE, NATR, and ALDXShould you be buying Allakos stock or one of its competitors? The main competitors of Allakos include Gossamer Bio (GOSS), Q32 Bio (QTTB), Cryoport (CYRX), AC Immune (ACIU), COMPASS Pathways (CMPS), Design Therapeutics (DSGN), Lyell Immunopharma (LYEL), Sage Therapeutics (SAGE), Nature's Sunshine Products (NATR), and Aldeyra Therapeutics (ALDX). These companies are all part of the "pharmaceutical preparations" industry. Allakos vs. Gossamer Bio Q32 Bio Cryoport AC Immune COMPASS Pathways Design Therapeutics Lyell Immunopharma Sage Therapeutics Nature's Sunshine Products Aldeyra Therapeutics Gossamer Bio (NASDAQ:GOSS) and Allakos (NASDAQ:ALLK) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, community ranking, media sentiment and profitability. Do insiders & institutionals believe in GOSS or ALLK? 81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 84.6% of Allakos shares are owned by institutional investors. 5.0% of Gossamer Bio shares are owned by company insiders. Comparatively, 16.1% of Allakos shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has stronger earnings and valuation, GOSS or ALLK? Gossamer Bio has higher revenue and earnings than Allakos. Gossamer Bio is trading at a lower price-to-earnings ratio than Allakos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGossamer Bio$105.32M1.50-$179.82M-$0.32-2.18AllakosN/AN/A-$185.70M-$2.03-0.46 Is GOSS or ALLK more profitable? Gossamer Bio's return on equity of -127.28% beat Allakos' return on equity.Company Net Margins Return on Equity Return on Assets Gossamer BioN/A -127.28% -22.12% Allakos N/A -140.87%-86.22% Which has more risk & volatility, GOSS or ALLK? Gossamer Bio has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500. Comparatively, Allakos has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Does the MarketBeat Community favor GOSS or ALLK? Allakos received 32 more outperform votes than Gossamer Bio when rated by MarketBeat users. However, 66.23% of users gave Gossamer Bio an outperform vote while only 59.22% of users gave Allakos an outperform vote. CompanyUnderperformOutperformGossamer BioOutperform Votes15166.23% Underperform Votes7733.77% AllakosOutperform Votes18359.22% Underperform Votes12640.78% Does the media prefer GOSS or ALLK? In the previous week, Gossamer Bio had 5 more articles in the media than Allakos. MarketBeat recorded 6 mentions for Gossamer Bio and 1 mentions for Allakos. Allakos' average media sentiment score of 0.66 beat Gossamer Bio's score of 0.59 indicating that Allakos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allakos 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer GOSS or ALLK? Gossamer Bio currently has a consensus target price of $9.20, indicating a potential upside of 1,220.89%. Allakos has a consensus target price of $1.67, indicating a potential upside of 77.46%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Allakos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Allakos 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 SummaryGossamer Bio beats Allakos on 11 of the 16 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Allakos News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALLK vs. The Competition Export to ExcelMetricAllakosPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$83.91M$6.45B$5.06B$8.82BDividend YieldN/A8.11%5.18%4.07%P/E Ratio-0.4610.78126.3117.81Price / SalesN/A243.711,178.7474.57Price / CashN/A22.1633.8632.53Price / Book0.495.474.684.68Net Income-$185.70M$153.61M$119.54M$226.08M7 Day Performance-20.41%-2.00%-1.83%-1.04%1 Month Performance10.07%-7.46%-3.60%1.04%1 Year Performance-46.94%31.82%31.91%26.28% Allakos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALLKAllakos4.3551 of 5 stars$0.94-6.9%$1.67+77.5%-50.8%$83.91MN/A-0.46131GOSSGossamer Bio4.4287 of 5 stars$0.70-2.8%$9.20+1,220.9%-16.9%$157.83M$105.32M-2.19180QTTBQ32 Bio1.6079 of 5 stars$27.28-6.2%$72.33+165.2%N/A$332.30M$-6,651,000.00-1.9139High Trading VolumeCYRXCryoport2.7225 of 5 stars$6.57-5.2%$12.50+90.3%-52.6%$324.76M$233.26M-1.941,170Insider TradeACIUAC Immune2.2991 of 5 stars$3.24-0.9%$12.00+270.4%+0.0%$320.57M$16.48M-7.09140Positive NewsCMPSCOMPASS Pathways2.8433 of 5 stars$4.66-2.1%$30.67+558.1%-23.0%$318.84MN/A-2.12120Short Interest ↓DSGNDesign Therapeutics1.7551 of 5 stars$5.48flat$7.00+27.7%+145.7%$310.28MN/A-6.4540LYELLyell Immunopharma0.5018 of 5 stars$1.03-7.2%$1.00-2.9%-46.9%$309.93M$130,000.000.00270High Trading VolumeSAGESage Therapeutics4.2604 of 5 stars$4.91flat$12.89+162.5%-75.1%$300.36M$86.46M0.00690Analyst ForecastNews CoverageGap DownNATRNature's Sunshine Products2.7901 of 5 stars$16.00+0.2%$19.00+18.8%-7.5%$295.68M$445.32M18.18814Positive NewsALDXAldeyra Therapeutics1.6557 of 5 stars$4.76-3.6%$10.00+110.1%+78.9%$294.18MN/A0.0015Analyst Revision Related Companies and Tools Related Companies Gossamer Bio Competitors Q32 Bio Competitors Cryoport Competitors AC Immune Competitors COMPASS Pathways Competitors Design Therapeutics Competitors Lyell Immunopharma Competitors Sage Therapeutics Competitors Nature's Sunshine Products Competitors Aldeyra Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALLK) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allakos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allakos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
